Taken these together, we have added a His-tag to the antibody to be able to load a radioactive agent (Technetium) to the antibody for detection purposes. We have initially employed transgenic AD mouse models and i.v. administered radio-labeled antibody to the animals and performed SPECT imaging. We found a gradual increased tau imaging employing our antibody in the animal models upon AD development.
Thus, we are about to examine if the antibody may detect the destruction in AD brain patients compared to the control subjects.